# Cancer Epidemiology, Prevention & Control

> **NIH NIH P30** · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2020 · $26,996

## Abstract

PROJECT SUMMARY - CANCER EPIDEMIOLOGY, PREVENTION AND CONTROL (CEPaC)
The CEPaC program plays a central role in the scientific, clinical and public health mission of AECC, and is the
focal point for the translation of laboratory-based research into studies at the population level. The broad aims
of CEPaC are to conduct studies in human populations to determine the behavioral, environmental and
molecular etiologic risk factors that underlie cancer development and outcomes, (especially actionable targets
for screening, prevention, and treatment), and further, to implement interventions and test their effectiveness in
the community. CEPaC has long been recognized for its contributions to the study of HPV and to molecular
epidemiologic cancer research. However, in recent years, cancer prevention and control research has greatly
expanded, with a strong focus on the largely poor and minority Bronx population. CEPaC is organized into four
major themes: (i) Infectious Risk Factors, including oncogenic HPV, HIV, HCV, and the human microbiome; (ii)
Hormonal, Obesity, and Inflammation-Related Risk Factors; (iii) Genetic/Epigenetic Risk Factors; and (iv)
Cancer Prevention, Control, and Implementation Science, encompassing prevention, health care delivery,
health disparities, survivorship and outcomes, especially in the local catchment area. CEPaC research has
also been impactful on clinical guidelines and practice, and recent studies will maintain this trend. For example:
(i) CEPaC laboratory advancements led to the characterization of HPV sub-lineages and HPV DNA
methylation, both sufficiently associated with strong risk of cervical cancer and precancer with the potential to
improve the positive predictive value (PPV) of recently FDA-approved “primary HPV screening”; (ii) obese
women with normal insulin levels were shown to have no greater risk of incident post-menopausal breast
cancer than normal weight women with normal insulin, but those with elevated insulin had significantly
increased risk regardless of obesity status – results that demonstrate the importance of etiologic biomarkers in
risk stratification (e.g., versus obesity), characterizing possible carcinogenic pathways, and as targets for
chemoprevention; (iii) a novel signature of metastatic risk based on laboratory and animal model studies was
strongly associated with metastasis of ER+/HER2- tumors in postmenopausal women, and may have a role in
guiding treatment decisions; (iv) firefighters who worked at the 9/11 WTC disaster site were found to be at
increased risk of developing MUGUS, a precursor of multiple myeloma, leading to changes in monitoring
practices in this group. Finally, the recent Einstein/Montefiore merger has increased shared interest in
collaborative cancer prevention initiatives in the Bronx, including community needs assessment, defining
cancer-health priorities, community outreach, and studies of the impact of these initiatives. There are 30
program members from 14 departmen...

## Key facts

- **NIH application ID:** 9998889
- **Project number:** 5P30CA013330-48
- **Recipient organization:** ALBERT EINSTEIN COLLEGE OF MEDICINE
- **Principal Investigator:** HOWARD D STRICKLER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $26,996
- **Award type:** 5
- **Project period:** 1997-06-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9998889

## Citation

> US National Institutes of Health, RePORTER application 9998889, Cancer Epidemiology, Prevention & Control (5P30CA013330-48). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9998889. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*